Insights
Notes on AI work in regulated environments.
Not trend pieces. Short, opinionated notes on where projects get stuck, what governance work actually matters, and what regulated teams keep underestimating.
Pharma AIMarch 7, 2026
Pharma is spending more on AI. The bottleneck still is not the model.
Budgets are up. Models are better. But adoption keeps stalling on the same thing: nobody sorted the data governance layer underneath.
Read the governance note
Regulated OperationsMarch 8, 2026
Validation is quietly becoming the most expensive part of AI in regulated companies.
The prototype is cheap. The change control, documentation, and review cycles that follow are where months disappear.
Read the validation note